CA3054826A1 - Mk2 inhibitors, synthesis thereof, and intermediates thereto - Google Patents

Mk2 inhibitors, synthesis thereof, and intermediates thereto Download PDF

Info

Publication number
CA3054826A1
CA3054826A1 CA3054826A CA3054826A CA3054826A1 CA 3054826 A1 CA3054826 A1 CA 3054826A1 CA 3054826 A CA3054826 A CA 3054826A CA 3054826 A CA3054826 A CA 3054826A CA 3054826 A1 CA3054826 A1 CA 3054826A1
Authority
CA
Canada
Prior art keywords
compound
formula
base
salt
scheme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3054826A
Other languages
English (en)
French (fr)
Inventor
Gregg Brian Feigelson
Maryll E. Geherty
Richard Martin Heid Jr.
Mohit KOTHARE
Hon-Wah Man
Alexander L. Ruchelman
John F. Traverse
Kelvin Hin-Yeong Yong
Chengmin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Celgene CAR LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CAR LLC filed Critical Celgene CAR LLC
Publication of CA3054826A1 publication Critical patent/CA3054826A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
CA3054826A 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto Pending CA3054826A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472024P 2017-03-16 2017-03-16
US62/472,024 2017-03-16
PCT/US2018/022547 WO2018170203A1 (en) 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto

Publications (1)

Publication Number Publication Date
CA3054826A1 true CA3054826A1 (en) 2018-09-20

Family

ID=63523971

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054826A Pending CA3054826A1 (en) 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto

Country Status (8)

Country Link
US (2) US10894796B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596086A4 (cg-RX-API-DMAC7.html)
JP (1) JP7282039B2 (cg-RX-API-DMAC7.html)
CN (1) CN110678471B (cg-RX-API-DMAC7.html)
AU (1) AU2018236290B2 (cg-RX-API-DMAC7.html)
CA (1) CA3054826A1 (cg-RX-API-DMAC7.html)
MX (1) MX387359B (cg-RX-API-DMAC7.html)
WO (1) WO2018170203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4284805A1 (en) * 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN116643046B (zh) * 2023-05-30 2025-09-12 南昌市高新区人民医院(南昌大学第一附属医院高新医院) Mk2在癌症恶病质肌肉萎缩中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
JP5369173B2 (ja) 2008-04-22 2013-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン若しくはイソキノリン置換ｐ２ｘ７アンタゴニスト
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CN103189377B (zh) * 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
BR112013010564B1 (pt) * 2010-11-01 2021-09-21 Celgene Car Llc Compostos heterocíclicos e composições compreendendo os mesmos
DK2648516T3 (da) * 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
BR112015000399A2 (pt) 2012-07-10 2017-06-27 Ares Trading Sa derivados de pirazolil pirimidina
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
CN104177340A (zh) * 2013-05-22 2014-12-03 中国中化股份有限公司 一种新型的喹唑啉（硫）酮类化合物及其用途
EP3110874B1 (en) 2014-02-27 2018-03-21 Council of Scientific and Industrial Research Poly-benzimidazole with pyrene and anthracene flourophore
WO2016025561A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
RS62017B1 (sr) * 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
WO2017040449A1 (en) 2015-09-03 2017-03-09 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
US20210139501A1 (en) 2021-05-13
US20200102326A1 (en) 2020-04-02
US10894796B2 (en) 2021-01-19
AU2018236290A1 (en) 2019-09-19
US11655257B2 (en) 2023-05-23
AU2018236290B2 (en) 2022-06-02
WO2018170203A1 (en) 2018-09-20
JP2020510063A (ja) 2020-04-02
CN110678471A (zh) 2020-01-10
EP3596086A4 (en) 2020-12-16
MX2019010642A (es) 2019-10-17
JP7282039B2 (ja) 2023-05-26
MX387359B (es) 2025-03-18
EP3596086A1 (en) 2020-01-22
CN110678471B (zh) 2022-09-13

Similar Documents

Publication Publication Date Title
US11655257B2 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
AU2009331179B2 (en) Novel bicyclic heterocyclic compound
CN105814050B (zh) 用作tnf活性调节剂的吡唑并吡啶衍生物
CA2992408A1 (en) Substituted aza compounds as irak-4 inhibitors
CA3199496A1 (en) Heterocycle derivatives for treating trpm3 mediated disorders
AU2006242920A1 (en) 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
EP3773566A1 (en) Ox2r compounds
AU2023351608A1 (en) Fused ring compound and pharmaceutical containing same
WO2001068607A1 (en) Amide compounds and use thereof
JP2006522784A (ja) 炎症疾患の治療でｐ３８ＭＡＰキナーゼインヒビターとして使用の５‐アミノ‐２‐カルボニルチオフェン誘導体
WO2023020209A1 (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN117222628A (zh) 一种抑制细胞程序性死亡的化合物及其制备方法
JP2025520081A (ja) Ｔｒｐｍ３媒介性障害を治療するためのインドリジン誘導体
EP2771011A1 (en) Chemical compounds
CA3108792A1 (en) Novel heteroaromatic amide derivative and medicament containing the same
TW202321262A (zh) 磺醯亞胺醯胺化合物及其用途
US10093679B2 (en) Amino sulfonyl-based compounds, the preparation method therefor and use thereof
EP4011880A1 (en) Jak kinase inhibitor and use thereof
JP2025518047A (ja) ＴＲＰＭ３媒介性障害を治療するためのピラゾロ［１，５－ａ］ピリジン誘導体
JP2025518048A (ja) Ｔｒｐｍ３媒介性障害を治療するためのインダゾール誘導体
JPWO2009041475A1 (ja) ピラゾール−３−イル−ベンズアミド誘導体の製造方法
CN114075188A (zh) 芳香杂环酰胺类化合物及其制备方法和医药用途
WO1999032459A1 (en) Chymase inhibitors
US20030199542A1 (en) Farnesyltransferase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230207

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260427